Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

APC/C-mediated multiple monoubiquitylation provides an alternative degradation signal for cyclin B1.

Nevena V Dimova | Nathaniel A Hathaway | Byung-Hoon Lee | Donald S Kirkpatrick | Marie Lea Berkowitz | Steven P Gygi | Daniel Finley | Randall W King
Nature cell biology | 2012

The anaphase-promoting complex or cyclosome (APC/C) initiates mitotic exit by ubiquitylating cell-cycle regulators such as cyclin B1 and securin. Lys 48-linked ubiquitin chains represent the canonical signal targeting proteins for degradation by the proteasome, but they are not required for the degradation of cyclin B1. Lys 11-linked ubiquitin chains have been implicated in degradation of APC/C substrates, but the Lys 11-chain-forming E2 UBE2S is not essential for mitotic exit, raising questions about the nature of the ubiquitin signal that targets APC/C substrates for degradation. Here we demonstrate that multiple monoubiquitylation of cyclin B1, catalysed by UBCH10 or UBC4/5, is sufficient to target cyclin B1 for destruction by the proteasome. When the number of ubiquitylatable lysines in cyclin B1 is restricted, Lys 11-linked ubiquitin polymers elaborated by UBE2S become increasingly important. We therefore explain how a substrate that contains multiple ubiquitin acceptor sites confers flexibility in the requirement for particular E2 enzymes in modulating the rate of ubiquitin-dependent proteolysis.

Pubmed ID: 22286100

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NIGMS NIH HHS, United States
    Id: R56 GM066492
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM066492
  • Agency: NIGMS NIH HHS, United States
    Id: GM095526
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM095526
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM066492-07
  • Agency: NIGMS NIH HHS, United States
    Id: R37 GM043601
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM066492-08
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM066492-07S1
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM066492-09
  • Agency: NIGMS NIH HHS, United States
    Id: GM66492
  • Agency: NIGMS NIH HHS, United States
    Id: R56 GM066492-06

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Boston Biochem (tool)

RRID:SCR_004761

THIS RESOURCE IS NO LONGER IN SERVICE, documented on August 17, 2021. An Antibody supplier.

View all literature mentions

GenScript (tool)

RRID:SCR_002891

Commercial organization which provides life science services and products to researchers. They specialize in gene synthesis, peptide, protein, antibody and preclinical drug development service.

View all literature mentions